Geron Corp. (NASDAQ:GERN)’s share price traded down 2.5% on Thursday . The stock traded as low as $2.66 and last traded at $2.71, with a volume of 1,031,790 shares trading hands. The stock had previously closed at $2.78.

Several equities analysts have recently weighed in on the company. FBR & Co reaffirmed a “buy” rating on shares of Geron Corp. in a research note on Sunday, May 8th. Zacks Investment Research lowered Geron Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, May 10th. Two analysts have rated the stock with a sell rating and five have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus target price of $6.13.

The company has a market cap of $430.78 million and a PE ratio of 903.33. The company has a 50-day moving average of $2.68 and a 200-day moving average of $2.84.

Geron Corp. (NASDAQ:GERN) last announced its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.02. The company had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.38 million. During the same period in the prior year, the company earned ($0.06) earnings per share. The company’s revenue for the quarter was down 15.9% on a year-over-year basis. On average, equities research analysts predict that Geron Corp. will post ($0.24) earnings per share for the current fiscal year.

Several large investors recently made changes to their positions in the stock. Russell Frank Co bought a new stake in shares of Geron Corp. during the fourth quarter valued at approximately $1,099,000. Morgan Stanley increased its stake in shares of Geron Corp. by 194.2% in the fourth quarter. Morgan Stanley now owns 268,626 shares of the biopharmaceutical company’s stock valued at $1,300,000 after buying an additional 177,313 shares in the last quarter. Finally, California State Teachers Retirement System increased its stake in shares of Geron Corp. by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 292,950 shares of the biopharmaceutical company’s stock valued at $1,418,000 after buying an additional 5,223 shares in the last quarter.

Geron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc (Janssen). The Company operates through the segment, which includes discovery and development of therapeutic products for oncology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.